The diagnostic role of CT, MRI/MRCP, PET/CT, EUS and DWI in the differentiation of benign and malignant IPMN: A meta-analysis

被引：22

作者：

Liu, Hongjie ^{[1
]}

Cui, Yu ^{[2
]}

Shao, Jianping ^{[2
]}

Shao, Zhijiang ^{[2
]}

Su, Feng ^{[2
]}

Li, Yongyuan ^{[2
]}

机构：

[1] Fifth Cent Hosp, Dept Radiol, Tianjin, Peoples R China

[2] Fifth Cent Hosp, Dept Gen Surg, 41 Tanggu Zhejiang Rd, Tianjin 300450, Peoples R China

来源：

CLINICAL IMAGING | 2021年 / 72卷

关键词：

CT; MRI/MRCP; PET/CT; EUS; DWI; Intraductal papillary mucinous neoplasm (IPMN); Meta-analysis;

D O I：

10.1016/j.clinimag.2020.11.018

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Purpose: The objective of this study was to assess the diagnostic properties of computed tomography (CT), magnetic resonance imaging (MRI/MRCP) /Magnetic Resonance Cholangiopancreatography (MRCP), positron emission tomography/computed tomography (PET/CT), endoscopic ultrasound (EUS) and diffusion-weighted magnetic resonance imaging (DWI) in distinguishing benign and malignant intraductal papillary mucinous neoplasm (IPMN). Materials and methods: Eligible databases were searched for eligible studies, published through July 2020 on the diagnostic accuracy of these modalities. Diagnostic accuracy parameters, including sensitivity, specificity, diagnostic odds ratio (DOR), and summary receiver operating characteristic curves (SROC) were calculated. Meta-regression was performed to identify the source of heterogeneity. Results: In total, 28 studies were included. Pooled sensitivities for CT, MRI/MRCP, PET/CT, EUS and DWI were 0.7, 0.76, 0.8, 0.6 and 0.72, respectively. Pooled specificities were 0.78, 0.83, 0.9, 0.8 and 0.97. The DORs were 8, 16, 35, 6 and 88. The areas under the curve (AUC) of SROC for CT, MRI/MRCP/MRCP, PET/CT, EUS and DW were 0.8, 0.87, 0.92, 0.79 and 0.82, respectively. Conclusion: PET/CT showed the highest AUC and the overall diagnostic accuracy results support the use of MRI/ MRCP, PET/CT interchangeably as a first-line examination in the diagnosis of malignant IPMN. With regard to DWI, EUS and CT, each techniques have their advantages and supportive to MRI/MRCP.

引用

页码：183 / 193

页数：11

共 46 条

[11]

Baba T., Yamaguchi T., Ishihara T., Kobayashi A., Oshima T., Sakaue N., Et al., Distinguishing benign from malignant intraductal papillary mucinous tumors of the pancreas by imaging techniques, Pancreas, 29, 3, pp. 212-217, (2004)

[12]

Choi S.Y., Kim J.H., Yu M.H., Eun H.W., Lee H.K., Han J.K., Diagnostic performance and imaging features for predicting the malignant potential of intraductal papillary mucinous neoplasm of the pancreas: a comparison of EUS, contrast-enhanced CT and MRI, Abdominal Radiol (New York), 42, 5, pp. 1449-1458, (2017)

[13]

Hara T., Yamaguchi T., Ishihara T., Tsuyuguchi T., Kondo F., Kato K., Et al., Diagnosis and patient management of intraductal papillary-mucinous tumor of the pancreas by using peroral pancreatoscopy and intraductal ultrasonography, Gastroenterology, 122, 1, pp. 34-43, (2002)

[14]

Hong H.S., Yun M., Cho A., Choi J.Y., Kim M.J., Kim K.W., Et al., The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm, Clin Nucl Med, 35, 10, pp. 776-779, (2010)

[15]

Kang H.J., Lee J.M., Joo I., Hur B.Y., Jeon J.H., Jang J.Y., Et al., Assessment of malignant potential in Intraductal papillary mucinous neoplasms of the pancreas: comparison between multidetector CT and MR imaging with MR Cholangiopancreatography, Radiology, 279, 1, pp. 128-139, (2016)

[16]

Kawai M., Uchiyama K., Tani M., Onishi H., Kinoshita H., Ueno M., Et al., Clinicopathological features of malignant intraductal papillary mucinous tumors of the pancreas: the differential diagnosis from benign entities, Arch Surg, 139, 2, pp. 188-192, (2004)

[17]

Lee J.E., Choi S.Y., Min J.H., Yi B.H., Lee M.H., Kim S.S., Et al., Determining malignant potential of Intraductal papillary mutinous neoplasm of the pancreas: CT versus MRI by using revised 2017 international consensus guidelines, Radiology, 293, 1, pp. 134-143, (2019)

[18]

Monnings P., Belyaev O., Uhl W., Giese A., Tannapfel A., Koster O., Et al., Criteria for determining malignancy in pancreatic Intraductal papillary mucinous neoplasm based on computed tomography, Digestion, 94, 4, pp. 230-239, (2016)

[19]

Regenet N., Sauvanet A., Muscari F., Meunier B., Mariette C., Adham M., Et al., The value of (18)F-FDG positron emission tomography to differentiate benign from malignant intraductal papillary mucinous neoplasms: a prospective multicenter study, J Visc Surg, 157, pp. 387-394, (2020)

[20]

Sahani D.V., Kadavigere R., Blake M., Fernandez-Del Castillo C., Lauwers G.Y., Hahn P.F., Intraductal papillary mucinous neoplasm of pancreas: multi-detector row CT with 2D curved reformations—correlation with MRCP, Radiology, 238, 2, pp. 560-569, (2006)

← 1 2 3 4 5 →